2016年为止的骨・关节感染市场：医疗用影像及PCR方法促进早期诊断和治疗 是由出版商GBI Research在2011年02月所出版的。
这份英文市场调查报告书包含Pages: 121 价格从美金3500起跳。
全球的骨・关节感染治疗药市场从2009年的7亿美金到2016年为止扩大CAGR为8.1%、预测达12亿美金。此成长的主要理由为、患病率及诊断数的增加和感染症治疗用所新上市的抗生物质的使用扩大。但是将来、2015年和2016年分别对Zyvox和Cubicin的专利失效因此收益预计会减少。虽说如此、此领域的治疗药作为开发中的药剂收益収益的贡献上期待有缓和的影响。
本报告书内容包括:全球的骨・关节感染治疗药市场的分析、市场的收益趋势、各地区、治疗领域趋势、后期开发阶段的药剂介绍、及加入企业的竞争介绍等汇整、内容纲要摘记如下:
第1章 目录
第2章 2016年为止的骨・关节感染市场：介绍
第3章 市场概要
第4章 各地区环境
第5章 治疗环境
- 人工关节感染治疗药市场
- 骨髄炎治疗药市场
- 败血症性关节炎治疗药市场
第6章 生产线分析
第7章 竞争环境
第8章 M&A环境
第9章 附录
Abstract
GBI Research, the leading business intelligence provider has released its
latest research “Bone and Joint Infection Market to 2016 - Medical
Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment”,
which essentially provides insights on bone and joint therapeutics sales and
price forecasts until 2016. The report also examines the global bone and joint
infections therapies treatment usage patterns. In addition, the geographical
distribution of bone and joint infections therapies across the US, the top
five countries in the European region and Japan are also provided in the
report. The report also includes insights into the bone and joint infections.
The report provides an in-depth analysis of the top three bone and joint
infections therapeutic indications, which are prosthetic joint infection,
osteomyelitis, and septic arthritis. Furthermore, it also includes the market
forecasts and treatment usage patterns of these three therapeutic indications.
The report also explores the competitive profiling for top companies. Finally,
the key trend analysis on Mergers and Acquisitions (M&As) and licensing
agreements involving bone and joint infections therapies is also presented.
It is built using data and information sourced from proprietary databases,
primary and secondary research and in-house analysis by GBI Research’s
team of industry experts.
The Bone and Joint Infections Market is Forecast to Growth to 2016
GBI research analysis suggests that the global bone and joint infections
therapeutics market was worth $0.7 billion in 2009 and this is forecast to
grow at a Compound Annual Growth Rate (CAGR) of 8.1% over the next seven years
to reach $1.2 billion by 2016. The main reasons for this growth are the rise
in the prevalence and diagnosis of bone and joint infections and the
increasing use of newly launched antibiotics for the treatment of such
infections. However, future market revenue is forecasted to be reduced due to
the impact of the patent expiry of Zyvox and Cubicin in 2015 and 2016
respectively. Nevertheless, this impact is expected to be softened by the
increase in the revenue contribution of pipeline products for the treatment of
complicated bone and joint infections.
Competition among Marketed Products is Strong in the Bone and Joint Infections
Therapeutics Market
GBI Research has analyzed the current competitive landscape for bone and joint
infections therapeutics drugs and has found the competition to be strong.
There are more than 30 types of antibiotics used to treat bone and joint
infections. Almost all the marketed products have strong efficacy and good
safety profiles. In addition, many generic products, such as penicillins, are
available at low cost so therefore there is intense competition in the market.
Quinolones, penicillins, aminoglycosides, carbpenems and many other generics
have emerged as the most prescribed antibiotics for bone and joint infections
due to their excellent efficacy and safety profiles. They have replaced
oxacillins, vancomycin, daptomycin,and third and fourth generation
cephalosporins as the first-choice of treatment, despite the latter being
recommended as the therapeutic option in the guidelines of major international
institutions. The patent expiry of Zyvox and Cubicin may increase the
competition in the market. Cephalosporins are expected to capture most of the
market available for other generics due to their efficacious advantage.
Efficacy and Safety Profiles of Off-Patent Marketed Products Decreases Market
Attractiveness for New Entrants
GBI Research has found that the global bone and joint infections therapeutics
market is not very attractive for investors looking to generate significant
revenues from the market. The market has highly efficacious drugs with good
safety profiles and therefore the currently marketed products meet the needs
of most of the patient population. In addition, highly prescribed antibiotics
such as quinolones, penicillins, aminoglycosides, cephalosporins, and
carbapenems are already available as low cost generics. The unmet needs in the
market are very small for investors to capitalize on. These unmet needs are
due to the increasing bacterial resistance to the current set of antibiotics.
Pharmaceutical companies are therefore focusing on the development of
antibiotics for resistant strains and are most active in this area of clinical
development. Molecules that can treat strains resistant to most of the
prescribed therapies are expected to cover the unmet needs of the bone and
joint infections therapeutics market.
Summary
GBI Research, the leading business intelligence provider, has released its
latest research “Bone and Joint Infection Market to 2016- Medical
Imaging and PCR methods to Facilitate Early Diagnosis and Treatment”,
which provides insights into bone and joint infections market sales and price
forecasts until 2016. The report also examines the global bone and joint
infections therapies treatment usage patterns. In addition, the geographical
distribution of bone and joint infections therapies across the US, the top
five countries in the European region and Japan are also provided in the
report. The report provides an in-depth analysis of the top three bone and
joint infections market therapeutic indications, which are prosthetic joint
infection, osteomyelitis and septic arthritis. Furthermore, it also includes
the market forecasts and treatment usage patterns of these these therapeutic
indications. Finally, the key trend analysis on Mergers and Acquisitions
(M&As) and licensing agreements involving bone and joint infections therapies
is also presented.
In-depth analysis of the report is based on propriety databases, primary and
secondary research and in-house analysis by the GBI Research team of
experts.
GBI Research analysis showed that the global bone and joint infections market
was estimated at $0.7 billion in 2009, with a year-on-year growth rate of 6.4%
between 2001 and 2009. GBI Research forecasts that the market will grow at a
Compound Annual Growth Rate (CAGR) of 8.1% between 2009 and 2016 to record a
sales value of $1.2 billion. The patent expiry of two of the branded drugs by
2016 is expected to make way for the entry of generics.
Many of the major pharmaceutical companies such as GlaxoSmithKline, Hoffman-La
Roche, Ranbaxy, Bayer AG, Teva Pharmaceuticals, Eli Lilly, Pfizer, Hospira,
Leo pharma A/S, App pharmaceuticals and Abbott are either entering or
expanding into the market. They are collaborating with or acquiring small and
medium-sized enterprises (SME) biotechnology companies. The main factor that
is driving the big pharmaceutical companies towards the bone and joint
infections therapeutics market is the increasing market for infectious
diseases mainly indications related to infections caused due to staphylococcus
species. As staphylococcus aureus is one of the major causative organisms for
infectious diseases. Bone and joint infections is one of the most common
infectious diseases.
Scope
• Data and analysis on the bone and joint infections market in the
leading geographies of the world - the US, the UK, Germany, France,
Italy, Spain, and Japan.
• Annualized market data for the bone and
joint infections market from 2001 to 2009, with forecasts to 2016.
•
Market data on the geographical landscape and therapeutic landscape, including
market size, market share, annual cost of therapy and treatment usage patterns
such as disease population, treatment seeking population, diagnosis population
and prescription population.
• Key drivers and restraints that have
had a significant impact on the market.
• The top companies
benchmarking in the bone and joint infections therapeutics market The key
companies studied in this report are GlaxoSmithKline, Hoffman-La Roche,
Ranbaxy, Bayer AG, Teva Pharmaceuticals, Eli Lilly, Pfizer, Hospira, Leo
pharma A/S, App pharmaceuticals and Abbott.
• Key M&A activities and
Licensing Agreements that took place in 2008 and 2009 in the bone and joint
infections market.
Reasons to buy
The report will assist business development and marketing executives to
strategize their product launches, by allowing them to -
• Build
effective strategies to launch their pipeline products by identifying
potential geographies.
• Exploit in-licensing and out-licensing
opportunities by identifying products that might fill their portfolio
gaps.
• Develop key strategic initiatives by studying the key
strategies of top competitors.
• Develop market-entry and market
expansion strategies by identifying the geographic markets poised for strong
growth.
• Reinforce R&D pipelines by identifying new target
mechanisms which can produce first-in-class molecules which are safer and more
efficacious.
Table of Contents
1. Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
2. Bone and Joint Infecmtion Market to 2016: Introduction
- 2.1 GBI Research Report Guidance
3. Bone and Joint Infection Market to 2016: Market Overview
- 3.1 Introduction
- 3.2 Revenue Forecasts for the Global Bone and Joint Infection Market
- 3.2.1 Revenue
- 3.2.2 Annual Cost of Treatment (ACT)
- 3.2.3 Treatment Usage Patterns
4. Bone and Joint Infection Market to 2016: Geographical Landscape
- 4.1 Revenue Analysis by Geography
- 4.2 The US
- 4.2.1 Revenue
- 4.2.2 Annual Cost of Treatment (ACT)
- 4.2.3 Treatment Usage Patterns
- 4.3 Top Five Countries in Europe
- 4.3.1 Revenue
- 4.3.2 Annual Cost of Treatment (ACT)
- 4.3.3 Treatment Usage Patterns
- 4.4 Japan
- 4.4.1 Revenue
- 4.4.2 Annual Cost of Treatment (ACT)
- 4.4.3 Treatment Usage Patterns
5. Bone and Joint Infection Market to 2016: Therapeutic Landscape
- 5.1 Prosthetic Joint Infections Therapeutics Market
- 5.1.1 Introduction
- 5.1.2 Revenue
- 5.1.3 Annual Cost of Treatment
- 5.1.4 Treatment Usage Patterns
- 5.1.5 Drivers and Barriers for the Prosthetic Joint Infections
Therapeutics Market
- 5.1.6 Drivers for the Prosthetic Joint Infections Therapeutics Market
- 5.1.7 Barriers for the Prosthetic Joint Infections Therapeutics Market
- 5.1.8 Opportunity and Unmet Need
- 5.2 Osteomyelitis Therapeutics Market
- 5.2.1 Introduction
- 5.2.2 Revenue
- 5.2.3 Annual Cost of Treatment (ACT)
- 5.2.4 Treatment Usage Patterns
- 5.2.5 Drivers and Barriers for the Osteomyelitis Therapeutics Market
- 5.2.6 Drivers for the Osteomyelitis Therapeutics Market
- 5.2.7 Barriers for the Osteomyelitis Therapeutics Market
- 5.2.8 Opportunity and Unmet Need
- 5.3 Septic Arthritis Therapeutics Market
- 5.3.1 Introduction
- 5.3.2 Revenue
- 5.3.3 Annual Cost of Treatment (ACT)
- 5.3.4 Treatment Usage Patterns
- 5.3.5 Drivers and Barriers for the Septic Arthritis Therapeutics Market
- 5.3.6 Drivers for the Septic Arthritis Therapeutics Market
- 5.3.7 Barriers for the Septic Arthritis Therapeutics market
- 5.3.8 Opportunity and Unmet Need
6. Bone and Joint Infection Market to 2016: Pipeline Analysis
- 6.1 Introduction
- 6.1.1 Research and Development Pipeline-Bone and Joint Infection
- 6.2 Profiles of Key Late Stage Drugs in the Bone and Joint Infection Market
- 6.2.1 Pagibaximab
- 6.2.2 TAKSTA
- 6.2.3 V710
- 6.2.4 Ceftobiprole
- 6.2.5 Teflaro
- 6.2.6 Torezolid
- 6.2.7 Rotarix + Infanrix + Pediarix + GSK 208108 + Prevnar 13
7. Bone and Joint Infection Market to 2016: Competitive Landscape
- 7.1 Overview
- 7.2 Competitive Profiling
- 7.2.1 Sandoz GmbH
- 7.2.2 GlaxoSmithKline
- 7.2.3 F. Hoffmann-La Roche Ltd.
- 7.2.4 Ranbaxy
- 7.2.5 Bayer AG
- 7.2.6 Teva Pharmaceutical Industries Limited
- 7.2.7 Eli Lilly and Company
- 7.2.8 Pfizer Inc.
- 7.2.9 Hospira, Inc.
- 7.2.10 LEO Pharma A/S
- 7.2.11 APP Pharmaceuticals, Inc.
- 7.2.12 Abbott Laboratories
8. Bone and Joint Infection Market to 2016: M&A Landscape
- 8.1 Global Bone and Joint Infection Market
- 8.1.1 Overview: Deals by Type
- 8.2 Mergers and Acquisitions
- 8.2.1 Overview
- 8.2.2 Durata Therapeutics Acquires Vicuron Pharmaceuticals
- 8.2.3 Aptuit Acquires Medicines Research Centre from GlaxoSmithKline
- 8.2.4 Hospira Acquires Pliva
- 8.3 Licensing Agreements
- 8.3.1 GlaxoSmithKline (GSK) and Isis Pharmaceuticals
- 8.3.2 Sanofi-aventis and Novozymes
- 8.3.3 Deals by Geography
- 8.3.4 Deals by Year
9. Bone and Joint Infection Market to 2016: Appendix
- 9.1 Market Definition
- 9.2 Abbreviations
- 9.3 Research Methodology
- 9.3.1 Coverage
- 9.3.2 Secondary Research
- 9.3.3 Forecasting
- 9.3.4 Primary Research
- 9.3.5 Expert Panels
- 9.4 Contact Us
- 9.5 Disclaimer
- 9.6 Sources
List of Tables:
- Table 1: Bone and Joint Infection Market, Global, Revenue ($bn), 2001-2009
- Table 2: Bone and Joint Infection Market, Global, Revenue Forecasts ($bn),
2009-2016
- Table 3: Bone and Joint Infection Market, Global, Annual Cost of Treatment
($), 2001-2009
- Table 4: Bone and Joint Infection Market, Global, Annual Cost of Treatment
($), 2009-20016
- Table 5: Bone and Joint Infection Market, Global, Treatment Usage Patterns
(thousands), 2001 -2009
- Table 6: Bone and Joint Infection Market, Global, Treatment Usage Patterns
(thousands), 2009 -2016
- Table 7: Bone and Joint Infection Market, Global, Diseased Population
(thousands) 2001-2009
- Table 8: Bone and Joint Infection Market, Global, Diseased Population
(thousands) 2009-2016
- Table 9: Bone and Joint Infection Market, Global, Treatment Seeking
Population (thousands) 2001-2009
- Table 10: Bone and Joint Infection Market, Global, Treatment Seeking
Population (thousands) 2009-2016
- Table 11: Bone and Joint Infection Market, Global, Diagnosed Population
(thousands), 2001-2009
- Table 12: Bone and Joint Infection Market, Global, Diagnosed Population
(thousands) 2009-2016
- Table 13: Bone and Joint Infection Market, Global, Prescription Population
(thousands) 2001-2009
- Table 14: Bone and Joint Infection Market, Global, Prescription Population
(thousands) 2009-2016
- Table 15: Bone and Joint Infection Market, Global, Revenue Analysis by
Geography ($m), 2001-2009
- Table 16: Bone and Joint Infection Market, Global, Revenue Analysis by
Geography ($m), 2009-2016
- Table 17: Bone and Joint Infection Market, The US, Revenue ($m), 2001-2009
- Table 18: Bone and Joint Infection Market, The US, Revenue Forecast ($m),
2009-2016
- Table 19: Bone and Joint Infection Market, The US, Annual Cost of
Treatment($), 2001-2009
- Table 20: Bone and Joint Infection Market, The US, Annual Cost of
Treatment($), 2009-2016
- Table 21: Bone and Joint Infection Market, The US, Treatment Usage
Patterns, 2001-2009
- Table 22: Bone and Joint Infection Market, The US, Treatment Usage
Patterns, 2009-2016
- Table 23: Bone and Joint Infection Market, The US, Diseased Population
(thousands) 2001-2009
- Table 24: Bone and Joint Infection Market, The US, Diseased Population
(thousands) 2009-2016
- Table 25: Bone and Joint Infection Market, The US, Treatment Seeking
Population (thousands) 2001-2009
- Table 26: Bone and Joint Infection Market, The US, Treatment Seeking
Population (thousands) 2009-2016
- Table 27: Bone and Joint Infection Market, The US, Diagnosed Population
(thousands) 2001-2009
- Table 28: Bone and Joint Infection Market, The US, Diagnosed Population
(thousands) 2009-2016
- Table 29: Bone and Joint Infection Market, The US, Prescription Population
(thousands) 2001-2009
- Table 30: Bone and Joint Infection Market, The US, Prescription Population
(thousands) 2009-2016
- Table 31: Bone and Joint Infection Market, Top Five countries in Europe,
Revenue ($m), 2001-2009
- Table 32: Bone and Joint Infection Market, Top Five countries in Europe,
Revenue Forecasts ($m), 2009-2016
- Table 33: Bone and Joint Infection Market, Top Five Countries in Europe,
Annual Cost of Treatment ($), 2001-2009
- Table 34: Bone and Joint Infection Market, Top Five Countries in Europe,
Annual Cost of Treatment ($), 2009-2016
- Table 35: Bone and Joint Infection Market, Top Five Countries in Europe,
Treatment Usage Patterns (thousands), 2001-2009
- Table 36: Bone and Joint Infection Market, Top Five Countries in Europe,
Treatment Usage Patterns (thousands), 2009-2016
- Table 37: Bone and Joint Infection Market, Top Five Countries in Europe,
Diseased Population (thousands) 2001-2009
- Table 38: Bone and Joint Infection Market, Top Five Countries in Europe,
Diseased Population (thousands) 2009-2016
- Table 39: Bone and Joint Infection Market, Top Five Countries in Europe,
Treatment Seeking Population (thousands) 2001-2009
- Table 40: Bone and Joint Infection Market, Top Five Countries in Europe,
Treatment Seeking Population (thousands) 2009-2016
- Table 41: Bone and Joint Infection Market, Top Five Countries in Europe,
Diagnosed Population (thousands) 2001-2009
- Table 42: Bone and Joint Infection Market, Top Five Countries in Europe,
Diagnosed Population (thousands) 2009-2016
- Table 43: Bone and Joint Infection Market, Top Five Countries in Europe,
Prescription Population (thousands) 2001-2009
- Table 44: Bone and Joint Infection Market, Top Five Countries in Europe,
Prescription Population (thousands) 2009-2016
- Table 45: Bone and Joint Infection Market, Japan, Revenue ($m), 2001-2009
- Table 46: Bone and Joint Infection Market, Japan, Revenue ($m), 2009-2016
- Table 47: Bone and Joint Infection Market, Japan, Annual Cost of Treatment
($), 2001-2009
- Table 48: Bone and Joint Infection Market, Japan, Annual Cost of
Treatment($), 2009-2016
- Table 49: Bone and Joint Infection Market, Japan, Treatment Usage Patterns
(thousands), 2001-2009
- Table 50:Bone and Joint Infection Market, Japan, Treatment Usage Patterns
(thousands), 2009-2016
- Table 51: Bone and Joint Infection Market, Japan, Diseased Population
(thousands) 2001-2009
- Table 52: Bone and Joint Infection Market, Japan, Diseased Population
(thousands) 2009-2016
- Table 53: Bone and Joint Infection Market, Japan, Treatment Seeking
Population (thousands) 2001-2009
- Table 54: Bone and Joint Infection Market, Japan, Treatment Seeking
Population (thousands) 2009-2016
- Table 55: Bone and Joint Infection Market, Japan, Diagnosed Population
(thousands) 2001-2009
- Table 56: Bone and Joint Infection Market, Japan, Diagnosed Population
(thousands) 2009-2016
- Table 57: Bone and Joint Infection Market, Japan, Prescription Population
(thousands) 2001-2009
- Table 58: Bone and Joint Infection Market, Japan, Prescription Population
(thousands) 2009-2016
- Table 59: Prosthetic Joint Infections Therapeutics Market, Global, Revenue
($m), 2001-2009
- Table 60: Prosthetic Joint Infections Therapeutics Market, Global, Revenue
Forecast ($m), 2009-2016
- Table 61: Prosthetic Joint Infections Therapeutics Market, Global, Annual
Cost of Treatment ($), 2001-2009
- Table 62: Prosthetic Joint Infections Therapeutics Market, Global, Annual
Cost of Treatment($), 2009-2016
- Table 63: Prosthetic Joint Infections Therapeutics Market, Global,
Treatment Usage Patterns (thousands), 2001-2009
- Table 64: Prosthetic Joint Infection Therapeutics Market, Global,
Treatment Usage Patterns (thousands), 2009-2016
- Table 65: Prosthetic Joint Infections Therapeutics Market, Global,
Diseased Population (thousands), 2001-2009
- Table 66: Prosthetic Joint Infections Therapeutics Market, Global,
Diseased Population (thousands), 2009-2016
- Table 67: Prosthetic Joint Infections Therapeutics Market, Global,
Treatment Seeking Population (thousands), 2001-2009
- Table 68: Prosthetic Joint Infections Therapeutics Market, Global,
Treatment Seeking Population (thousands), 2009-2016
- Table 69: Prosthetic Joint Infections Therapeutics Market, Global,
Diagnosed Population (thousands), 2001-2009
- Table 70: Prosthetic Joint Infections Therapeutics Market, Global,
Diagnosed Population (thousands), 2009-2016
- Table 71: Prosthetic Joint Infections Therapeutics Market, Global,
Prescription Population (thousands), 2001-2009
- Table 72: Prosthetic Joint Infections Therapeutics Market, Global,
Prescription Population (thousands), 2009-2016
- Table 73: Osteomyelitis Therapeutics Market, Global, Revenue ($m),
2001-2009
- Table 74: Osteomyelitis Therapeutics Market, Global, Revenue Forecast
($m), 2009-2016
- Table 75: Osteomyelitis Therapeutics Market, Global, Annual Cost of
Treatment ($), 2001-2009
- Table 76: Osteomyelitis Therapeutics Market, Global, Annual Cost of
Treatment ($), 2009-2016
- Table 77: Osteomyelitis Therapeutics Market, Global, Treatment Usage
Patterns (thousands), 2001-2009
- Table 78: Osteomyelitis Therapeutics Market, Global, Treatment Usage
Patterns (thousands), 2009-2016
- Table 79: Osteomyelitis Therapeutics Market, Global, Diseased Population
(thousands), 2001-2009
- Table 80: Osteomyelitis Therapeutics Market, Global, Diseased Population
(thousands), 2009-2016
- Table 81: Osteomyelitis Therapeutics Market, Global, Treatment Seeking
Population (thousands), 2001-2009
- Table 82: Osteomyelitis Therapeutics Market, Global, Treatment Seeking
Population (thousands), 2009-2016
- Table 83: Osteomyelitis Therapeutics Market, Global, Diagnosed Population
(thousands),2001-2009
- Table 84: Osteomyelitis Therapeutics Market, Global, Diagnosed Population
(thousands),2009-2016
- Table 85: Osteomyelitis Therapeutics Market, Global, Prescription
Population (thousands), 2001-2009
- Table 86: Osteomyelitis Therapeutics Market, Global, Prescription
Population (thousands), 2009-2016
- Table 87: Septic Arthritis Therapeutics Market, Global, Revenue ($m),
2001-2009
- Table 88: Septic Arthritis Therapeutics Market, Global, Revenue Forecast
($m), 2009-2016
- Table 89: Septic Arthritis Therapeutics Market, Global, Annual Cost of
Treatment ($), 2001-2009
- Table 90: Septic Arthritis Therapeutics Market, Global, Annual Cost of
Treatment ($), 2009-2016
- Table 91: Septic Arthritis Therapeutics Market, Global, Treatment Usage
Patterns (thousands), 2001-2009
- Table 92: Septic Arthritis Therapeutics Market, Global, Treatment Usage
Patterns (thousands), 2009-2016
- Table 93: Septic Arthritis Therapeutics Market, Global, Diseased
Population (thousands), 2001-2009
- Table 94: Septic Arthritis Therapeutics Market, Global, Diseased
Population (thousands), 2009-2016
- Table 95: Septic Arthritis Therapeutics Market, Global, Treatment Seeking
Population (thousands), 2001-2009
- Table 96: Septic Arthritis Therapeutics Market, Global, Treatment Seeking
Population (thousands), 2009-2016
- Table 97: Septic Arthritis Therapeutics Market, Global, Diagnosed
Population (thousands), 2001-2009
- Table 98: Septic Arthritis Therapeutics Market, Global, Diagnosed
Population (thousands), 2009-2016
- Table 99: Septic Arthritis Therapeutics Market, Global, Prescription
Population (thousands), 2001-2009
- Table 100:Septic Arthritis Therapeutics Market, Global, Prescription
Population (thousands), 2009-2016
- Table 101:Bone and Joint Infection Market, Pipeline, Discovery Stage
Molecules, 2010
- Table 102:Bone and Joint Infection Market, Pipeline, Preclinical
Molecules, 2010
- Table 103:Bone and Joint Infection Market, Pipeline, Phase I Molecules,
2010
- Table 104:Bone and Joint Infection Market, Pipeline, Phase II Molecules,
2010
- Table 105:Bone and Joint Infection Market, Pipeline, Phase II Molecules,
2010
- Table 106:Bone and Joint Infection Market, Pipeline, Filed Molecules, 2010
- Table 107:Bone and Joint Infection Market, Global, Major M&A Deals,
2008-2010
List of Figures
- Figure 1: Bone and Joint Infection Market, Global, Revenue Forecasts
($bn), 2001-2016
- Figure 2: Bone and Joint Infection Market, Global, Annual Cost of
Treatment ($), 2001-2016
- Figure 3: Bone and Joint Infection Market, Global, Treatment Usage
Patterns (thousands), 2001-2016
- Figure 4: Bone and Joint Infection Market, Global, Diseased Population
(thousands) 2001-2016
- Figure 5: Bone and Joint Infection Market, Global, Treatment Seeking
Population (thousands) 2001-2016
- Figure 6: Bone and Joint Infection Market, Global, Diagnosed Population
(thousands) 2001-2016
- Figure 7: Bone and Joint Infection Market, Global, Prescription Population
(thousands) 2001-2016
- Figure 8: Bone and Joint infections Market, Global, Revenue Analysis by
Geography ($bn), 2001-2016
- Figure 9: Bone and Joint Infection Market, The US, Revenue Forecasts ($m),
2001-2016
- Figure 10: Bone and Joint Infection Market, The US, Annual Cost of
Treatment ($), 2001-2016
- Figure 11: Bone and Joint Infection Market, The US, Treatment Usage
Patterns, 2001-2016
- Figure 12: Bone and Joint Infection Market, The US, Diseased Population
(thousands) 2001-2016
- Figure 13: Bone and Joint Infection Market, The US, Treatment Seeking
Population (thousands) 2001-2016
- Figure 14: Bone and Joint Infection Market, The US, Diagnosed Population
(thousands) 2001-2016
- Figure 15: Bone and Joint Infection Market, The US, Prescription
Population (thousands) 2001-2016
- Figure 16: Bone and Joint Infection Market, Top Five countries in Europe,
Revenue Forecasts ($m), 2001-2016
- Figure 17: Bone and joint infections Therapeutics Market, Top Five
Countries in Europe, Annual Cost of Treatment ($), 2001-2016
- Figure 18: Bone and Joint Infection Market, Top Five Countries in Europe,
Treatment Usage Patterns (thousands), 2001-2016
- Figure 19: Bone and Joint Infection Market, Top Five Countries in Europe,
Diseased Population (thousands), 2001-2016
- Figure 20: Bone and Joint Infection Market, Top Five Countries in Europe,
Treatment Seeking Population (thousands) 2001-2016
- Figure 21: Bone and Joint Infection Market, Top Five Countries in Europe,
Diagnosed Population (thousands) 2001-2016
- Figure 22: Bone and Joint Infection Market, Top Five Countries in Europe,
Diagnosed Population (thousands) 2001-2016
- Figure 23: Bone and Joint Infection Market, Japan, Revenue Forecast ($m),
2001-2016
- Figure 24: Bone and Joint Infection Market, Japan, Annual Cost of
Treatment ($), 2001-2016
- Figure 25: Bone and Joint Infection Market, Japan, Treatment Usage
Patterns (thousands), 2001-2016
- Figure 26: Bone and Joint Infection Market, Japan, Diseased Population
(thousands) 2001-2016
- Figure 27: Bone and Joint Infection Market, Japan, Treatment Seeking
Population (thousands) 2001-2016
- Figure 28: Bone and Joint Infection Market, Japan, Diagnosed Population
(thousands) 2001-2016
- Figure 29: Bone and Joint Infection Market, Japan, Prescription Population
(thousands) 2001-2016
- Figure 30: Prosthetic Joint Infections Therapeutics Market, Global,
Revenue Forecasts ($m), 2001-2016
- Figure 31: Prosthetic Joint Infections Therapeutics Market, Global, Annual
Cost of Treatment ($), 2001-2016
- Figure 32: Prosthetic Joint Infections Therapeutics Market, Global,
Treatment Usage Patterns (thousands), 2001-2016
- Figure 33: Prosthetic Joint Infections Therapeutics Market, Global,
Diseased Population (thousands), 2001-2016
- Figure 34: Prosthetic Joint Infections Therapeutics Market, Global,
Treatment Seeking Population (thousands), 2001-2016
- Figure 35: Prosthetic Joint Infections Therapeutics Market, Global,
Diagnosed Population (thousands), 2001-2016
- Figure 36: Prosthetic Joint Infections Therapeutics Market, Global,
Prescription Population (thousands), 2001-2016
- Figure 37: Prosthetic Joint Infections Therapeutics, Market Drivers and
Barriers, 2009-2016
- Figure 38: Osteomyelitis Therapeutics Market, Global, Revenue Forecasts
($m), 2001-2016
- Figure 39: Osteomyelitis Therapeutics Market, Global, Annual Cost of
Treatment ($), 2001-2016
- Figure 40: Osteomyelitis Therapeutics Market, Global, Treatment Usage
Patterns (thousands), 2001-2016
- Figure 41: Osteomyelitis Therapeutics Market, Global, Diseased Population
(thousands), 2001-2016
- Figure 42: Osteomyelitis Therapeutics Market, Global, Treatment Seeking
Population (thousands), 2001-2016
- Figure 43: Osteomyelitis Therapeutics Market, Global, Diagnosed Population
(thousands), 2001-2016
- Figure 44: Osteomyelitis Therapeutics Market, Global, Prescription
Population (thousands), 2001-2016
- Figure 45: Osteomyelitis Therapeutics Market, Global, Market Drivers and
Barriers, 2009-2016
- Figure 46: Septic Arthritis Therapeutics Market, Global, Revenue Forecasts
($m), 2001-2016
- Figure 47: Septic Arthritis Therapeutics Market, Global, Annual Cost of
Treatment ($), 2001-2016
- Figure 48: Septic Arthritis Therapeutics Market, Global, Treatment Usage
Patterns (thousands), 2001-2016
- Figure 49: Septic Arthritis Therapeutics Market, Global, Diseased
Population (thousands), 2001-2016
- Figure 50: Septic Arthritis Therapeutics Market, Global, Treatment Seeking
Population (thousands), 2001-2016
- Figure 51: Septic Arthritis Therapeutics Market, Global, Diagnosed
Population (thousands), 2001-2016
- Figure 52: Septic Arthritis Therapeutics Market, Global, Prescription
Population (thousands), 2001-2016
- Figure 53: Septic Arthritis Therapeutics Market, Global, Market Drivers
and Barriers, 2009-2016
- Figure 54: Arthritis Therapeutics Market, Global, R&D Pipeline by Phase
(%), 2010
- Figure 55: SWOT Analysis of Sandoz GmbH
- Figure 56: SWOT Analysis of GlaxoSmithKline
- Figure 57: SWOT Analysis of F.Hoffmann-La Roche Ltd.
- Figure 58: SWOT Analysis of Ranbaxy
- Figure 59: SWOT Analysis of Bayer AG
- Figure 60: SWOT Analysis of Teva Pharmaceutical Industries Limited
- Figure 61: SWOT Analysis of Eli-lilly and Company
- Figure 62: SWOT Analysis of Pfizer
- Figure 63: SWOT Analysis of Hospira, Inc
- Figure 64: SWOT Analysis of LEO Pharma A/S
- Figure 65: SWOT Analysis of APP Pharmaceuticals, Inc.
- Figure 66: SWOT Analysis of Abbott Laboratories
- Figure 67: Bone and Joint Infection Market, Global, Deals by Type,
2008-2010
- Figure 68: Bone and Joint Infection Market, Global, Major Deals By
Geography, 2008-2010
- Figure 69:Bone and Joint Infection Market, Global, Major Deals By Year,
2008-2010
- Figure 70: GBI Research Market Forecasting Model
|
